查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1808519

內分泌檢測市場按類型、產品類型、樣本類型、技術、疾病類型和最終用戶分類－2025-2030 年全球預測

Endocrine Testing Market by Type, Product Type, Sample Type, Technology, Disease Type, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2024年內分泌檢測市場價值將達到100.7億美元，2025年將成長至108.8億美元，複合年成長率為8.33%，到2030年將達到162.9億美元。

主要市場統計數據
預測年份（2024年） 100.7億美元
基準年（2025年） 108.8億美元
預測年份（2030年） 162.9億美元
複合年成長率（%） 8.33%

確定關鍵促進因素、新興創新和市場基本面，將荷爾蒙檢測置於現代醫療保健策略的前沿

內分泌檢測已成為現代醫學的重要支柱，支持多種荷爾蒙失調的診斷和治療。隨著檢測靈敏度的提高，以及對內分泌病理生理學理解的不斷加深，這些檢測已從常規臨床工具提升為推動以患者為中心的醫療的策略性槓桿。糖尿病、甲狀腺功能障礙和腎上腺疾病等疾病的日益流行，使得精準可靠的診斷方法變得愈加迫切。同時，個人化醫療的發展也對實驗室和檢測開發人員提出了新的要求，要求他們提供快速、多元且微創的解決方案。

檢驗由技術突破、監管改革和以患者為中心的護理模式推動的內分泌診斷變革

近年來，在尖端技術創新和監管預期變化的推動下，內分泌診斷領域發生了翻天覆地的變化。串聯式質譜質譜和高通量免疫測量融入核心實驗室工作流程，將檢測準確性和通量釋放了新的水平。同時，世界各地的監管機構也推出了更嚴格的驗證要求和品質基準，促使製造商在合規性和文件流程方面投入大量資金。

評估 2025 年美國關稅對動態經濟中內分泌檢測供應鏈和市場營運的累積影響

2025年，進口試劑、儀器和輔助用品將實施新的關稅制度，這使得內分泌檢測供應鏈的韌性成為關注的焦點。實驗室和儀器供應商面臨著不斷上升的投入成本，這促使籌資策略。許多公司正在加速供應商網路的多元化，並建立區域配送中心，以降低成本轉嫁和運輸延誤的風險。

揭示關鍵細分洞察，展示測試類型、產品類型、樣本介質、技術、疾病分類和最終用戶如何塑造市場

深入研究市場細分，可以發現支撐內分泌診斷生態系統的檢測類型和應用構成了複雜的網路。皮質醇檢測仍然是評估腎上腺功能的重要工具，而硫酸脫氫表雄酮檢測則已興起，用於評估腎上腺雄激素的生成。雌二醇檢測仍然是生殖健康監測的基石，人類絨毛膜促性腺激素分泌檢測則支持不孕症管理和懷孕監測。胰島素檢測對於血糖控制至關重要，性荷爾蒙檢測組可以提供全面的內分泌分析，甲狀腺刺激素分析是甲狀腺疾病管理的基石。

重點介紹美洲、歐洲、中東和非洲地區以及亞太地區的主要區域動態，揭示不同的需求模式、採用率和成長動力

內分泌檢測領域的區域動態呈現出顯著的多樣性，因為營運商需要應對不同的監管環境、報銷框架和患者人口結構。在美洲，成熟的報銷途徑和實驗室網路正在促進先進檢測平台的快速普及。學術中心與私人企業之間的合作研究計畫正在進一步加強創新管道，並使新型診斷方法的試點部署成為可能。

重點介紹影響全球內分泌檢測市場的策略聯盟、創新組合和競爭進步等關鍵產業參與者

內分泌診斷領域的主要參與企業正日益努力透過策略聯盟、產品組合合理化和技術創新來實現差異化。現有的試劑和儀器供應商正在與生物製藥公司合作開發伴隨診斷，而診斷專家則正在整合數位健康平台，以簡化數據管理和遠端監控。

為專注於技術整合、策略夥伴關係和內分泌診斷新興市場擴張的產業領導者提供可行的建議

產業領導者應採用能夠同時進行免疫檢測和質譜分析的靈活平台，加速下一代技術的整合。這種整合可以簡化工作流程並降低整體擁有成本。同時，與契約製造製造商和區域經銷商建立策略夥伴關係可以緩解供應鏈漏洞，並支援企業快速進入高成長地區市場。

了解我們全面的調查方法：透過一手數據、二手數據和數據三角測量，獲得嚴謹的市場洞察

本次分析採用嚴格的混合方法研究設計，以確保研究的全面覆蓋和嚴謹的分析。主要見解透過與高階主管、臨床實驗室主任、關鍵意見領袖和採購專家進行結構化訪談收集。這些對話揭示了當前營運挑戰、未滿足的需求以及整個價值鏈的策略重點。

觀點強調了指導全球內分泌檢測發展的策略重點、未來前景和綜合創新

內分泌檢測市場正處於曲折點，快速的技術進步、不斷變化的管理體制以及不斷變化的患者期​​望正在匯聚在一起，重新定義診斷範式。細分分析凸顯了臨床實驗室、研究機構和即時診斷 (POC) 提供者的多樣化需求，而區域洞察則強調了自適應打入市場策略的重要性。

目錄

第1章 引言

第2章分析方法

第3章執行摘要

第4章 市場概況

第5章市場動態

  • 提高對早期發現內分泌失調重要性的認知
  • 擴大就地檢驗設備的採用
  • 個人化醫療需求不斷成長推動客製化內分泌治療
  • 將人工智慧演算法融入內分泌測試解釋以提高診斷準確性
  • 採用多重免疫檢測平台同時篩檢多種荷爾蒙生物標記物
  • 家用試劑套件的出現，使得在臨床環境之外能持續監測激素
  • 建立超靈敏質譜法測定複雜基質中的微量激素
  • 擴大腫瘤學伴隨診斷揭示可預測治療反應的內分泌標記物
  • 加強監管，重點在於檢測標準化和品管，提高檢測可靠性
  • 增加對穿戴式生物感測器的投資，用於即時荷爾蒙監測和健康管理

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章：美國關稅的累積影響（2025年）

第8章內分泌檢測市場（按類型）

  • 皮質醇測試
  • 脫氫表雄酮硫酸鹽（DHEAS）測試
  • 雌二醇（E2）檢測
  • 人類絨毛膜促性腺激素分泌（hCG）檢測
  • 胰島素檢測
  • 性荷爾蒙檢測
  • 甲狀腺刺激素（TSH）檢測

第9章內分泌檢測市場（依產品類型）

  • 裝置
    • 層析法系統
    • 免疫檢測分析儀
    • 質譜儀系統
  • 試劑和套件
    • 校準器
    • 控制材料
    • 診斷試劑套件
  • 軟體和服務
    • 資訊學解決方案
    • 維護服務

第 10 章內分泌檢測市場（依樣本類型）

  • 血
  • 唾液
  • 尿

第11章內分泌檢測市場（依技術）

  • 臨床化學
  • 免疫檢測
  • 單株和多株抗體技術
  • 感測器技術
  • 串聯式質譜質譜法

第12章內分泌檢測市場（依疾病類型）

  • 腎上腺疾病
    • 愛迪生氏症
    • 庫欣氏症候群
  • 糖尿病
  • 性腺疾病
    • 性腺功能低下
    • 卵巢症候群
  • 甲狀腺功能障礙
    • 甲狀腺功能亢進
    • 甲狀腺機能低下症

第13章內分泌檢測市場（依最終用戶）

  • 學術機構
  • 診斷實驗室
  • 醫院和診所
  • 研究所

14.美國內分泌檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

15. 歐洲、中東和非洲內分泌檢測市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

16. 亞太地區內分泌檢測市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第17章競爭格局

  • 市場佔有率分析（2024年）
  • FPNV定位矩陣（2024年）
  • 競爭分析
    • Bio-Rad Laboratories Inc
    • bioMerieux SA
    • Abbott Laboratories
    • ACON Laboratories, Inc.
    • Agilent Technologies, Inc.
    • BioCheck Inc.
    • Biogenix Inc. Pvt. Ltd
    • Blueprint Genetics Oy
    • Creative Diagnostics
    • Danaher Corporation
    • Diagnostic Automation/Cortez Diagnostics Inc.
    • DiaSorin SpA
    • Eagle Biosciences
    • EKF Diagnostics Holdings Plc
    • Eurofins Analytical Laboratories Inc.
    • Getein Biotech, Inc.
    • Laboratory Corporation of America Holdings
    • MP Biomedicals, LLC
    • Ortho-Clinical Diagnostics, Inc.
    • Quest Diagnostics Incorporated
    • Randox Laboratories Ltd.
    • Shenzhen New Industries Biomedical Engineering Co., Ltd.
    • Siemens Healthcare GmbH
    • Thermo Fisher Scientific Inc.
    • Trivitron Healthcare
    • Eli Science Inc.
    • F. Hoffmann-La Roche Ltd

第18章 研究人工智慧

第19章 研究統計

第20章 研究聯絡人

第21章 研究報導

第22章 附錄

Product Code: MRR-69324464D0E6

The Endocrine Testing Market was valued at USD 10.07 billion in 2024 and is projected to grow to USD 10.88 billion in 2025, with a CAGR of 8.33%, reaching USD 16.29 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 10.07 billion
Estimated Year [2025] USD 10.88 billion
Forecast Year [2030] USD 16.29 billion
CAGR (%) 8.33%

Positioning Hormone Testing at the Forefront of Modern Healthcare Strategies by Highlighting Key Drivers, Emerging Innovations, and Market Foundations

The field of endocrine testing has emerged as a critical pillar of modern healthcare, underpinning the diagnosis and management of a wide array of hormonal disorders. Advances in assay sensitivity, coupled with an expanding understanding of endocrine pathophysiology, have elevated these tests from routine clinical tools to strategic instruments that drive patient-centric care. Increasing prevalence of conditions such as diabetes, thyroid dysfunction, and adrenal disorders has heightened the urgency for precise, reliable diagnostics. At the same time, personalized medicine initiatives are placing new demands on laboratories and test developers to deliver rapid, multiplexed, and minimally invasive solutions.

As regulatory agencies refine guidelines and reimbursement frameworks evolve, manufacturers and laboratories are compelled to reimagine their operational models. Investments in digital health platforms, artificial intelligence for data interpretation, and point-of-care testing are reshaping traditional workflows. This introduction establishes the foundational context for an in-depth exploration of how technological breakthroughs, tariff dynamics, segmentation strategies, regional variations, and competitive intelligence are collectively redefining the endocrine testing landscape.

Examining Transformative Shifts in Endocrine Diagnostics Fueled by Technological Breakthroughs, Regulatory Reforms, and Patient-Centric Care Models

In recent years, the endocrine diagnostics sector has undergone seismic shifts driven by cutting-edge technological innovation and changing regulatory expectations. The integration of tandem mass spectrometry and high-throughput immunoassays into core laboratory workflows has unlocked new levels of assay precision and throughput. Concurrently, regulatory agencies around the world have introduced more stringent validation requirements and quality benchmarks, prompting manufacturers to invest heavily in compliance and documentation processes.

Beyond the bench, patient empowerment and home-based testing models have emerged as transformative forces. Direct-to-consumer test offerings for hormone monitoring and telehealth platforms have blurred the boundaries between clinical settings and at-home care, fostering a more participatory approach to disease management. As laboratories and instrument providers adapt, strategic partnerships with digital health firms and data analytics companies are becoming increasingly commonplace. The confluence of these technological and patient-centric revolutions is redirecting capital flows, reshaping R&D priorities, and setting the stage for an era of highly personalized endocrine care.

Assessing the Cumulative Impact of United States Tariffs on Endocrine Testing Supply Chains and Market Operations throughout 2025 in a Dynamic Economy

The imposition of new tariff structures on imported reagents, instruments, and ancillary supplies in 2025 has cast a spotlight on the resilience of endocrine testing supply chains. Laboratories and instrument vendors have faced elevated input costs, prompting a comprehensive reassessment of procurement strategies. Many organizations are accelerating the diversification of their supplier networks and establishing regional distribution hubs to mitigate the risk of cost pass-through and shipment delays.

In response to these pressures, domestic manufacturers have seized the opportunity to expand production capacities, collaborating with local distributors to ensure continuity of service. End-users have initiated safety-stock buffering plans and negotiated long-term agreements to secure preferential pricing. Although upfront capital expenditures have risen, these strategic adjustments are laying the groundwork for more agile, de-risked operations. Ultimately, the tariff-driven recalibration of supply chains is fostering a renewed emphasis on localization, strategic inventory management, and operational flexibility.

Unveiling Critical Segmentation Insights That Demonstrate How Test Types, Product Categories, Sample Mediums, Technologies, Disease Classifications, and End Users Shape the Market

A deep dive into market segmentation reveals a complex tapestry of test types and applications that underpin the endocrine diagnostics ecosystem. Cortisol assays continue to serve as essential tools for evaluating adrenal function, while dehydroepiandrosterone sulfate testing has gained prominence in assessing adrenal androgen output. Estradiol measurement remains a cornerstone of reproductive health monitoring, and human chorionic gonadotropin testing supports both fertility management and pregnancy surveillance. Insulin assays are indispensable for glycemic control, sex hormone panels provide comprehensive endocrine profiling, and thyroid stimulating hormone analysis is foundational to thyroid disease management.

The instrumentation and consumable landscape is equally multifaceted. Chromatography systems, immunoassay analyzers, and mass spectrometry platforms represent the primary instrument categories driving laboratory modernization. Complementing these instruments, calibrators, control materials, and diagnostic kits enable rigorous quality assurance and assay standardization. Informatics solutions and maintenance services provide the digital infrastructure and technical support necessary to optimize uptime and data integrity.

Sample medium diversity further enriches testing approaches, encompassing blood draws, saliva collection, and urine samples to accommodate both conventional laboratory protocols and emerging at-home testing models. Underlying these modalities, a spectrum of technological platforms-including clinical chemistry, immunoassay, monoclonal and polyclonal antibody technologies, sensor innovations, and tandem mass spectrometry-delivers unparalleled sensitivity, specificity, and throughput.

Disease-centric segmentation highlights distinct demand drivers. The adrenal disorder segment, including Addison's disease and Cushing's syndrome, requires specialized assays for cortisol and adrenal androgens. Diabetes monitoring leverages insulin and related metabolic markers, whereas gonadal disorder evaluation, covering hypogonadism and polycystic ovary syndrome, relies on comprehensive sex hormone panels. Thyroid dysfunction analysis, spanning hyperthyroidism and hypothyroidism, centers on the precise quantification of thyroid stimulating hormone.

Finally, the end-user landscape spans academic institutions pursuing basic research, diagnostic laboratories implementing high-volume workflows, hospitals and clinics integrating point-of-care solutions, and research institutes driving translational discovery. Each segment presents unique operational requirements and strategic priorities, underscoring the importance of tailored solutions and collaboration across the value chain.

Highlighting Key Regional Dynamics across the Americas, Europe Middle East Africa, and Asia Pacific to Reveal Distinct Demand Patterns, Adoption Rates, and Growth Drivers

Regional dynamics within the endocrinology testing sphere exhibit pronounced diversity as operators navigate distinct regulatory landscapes, reimbursement frameworks, and patient demographics. In the Americas, well-established reimbursement pathways and mature laboratory networks facilitate rapid adoption of advanced assay platforms. Collaborative research initiatives between academic centers and commercial entities further bolster innovation pipelines and enable pilot deployments of novel diagnostic modalities.

The Europe, Middle East, and Africa region presents a heterogeneous tapestry of regulatory environments, from the European Union's harmonized directives to varied approval processes across Middle Eastern and African nations. This mosaic compels manufacturers to pursue adaptive market entry strategies, leveraging local partnerships and regulatory expertise. High population growth in certain markets augments demand for cost-effective, point-of-care solutions, while established institutions in Western Europe continue to demand high-precision laboratory instrumentation.

Across Asia-Pacific, rapid economic growth and expanding healthcare infrastructure are driving increased diagnostic investments. In countries with burgeoning middle-class populations, there is notable uptake of minimally invasive and at-home testing options. Governmental initiatives aimed at enhancing rural healthcare access are stimulating deployment of portable immunoassay systems and integrated telehealth platforms. Simultaneously, major regional manufacturers are investing in R&D to develop localized solutions that address endemic endocrine health challenges and align with national healthcare priorities.

Profiling Leading Industry Players to Showcase Strategic Collaborations, Innovation Portfolios, and Competitive Advances Shaping the Global Endocrine Testing Arena

Leading participants in the endocrine diagnostics arena are intensifying efforts to differentiate through strategic alliances, portfolio rationalization, and technological innovation. Established reagent and instrument providers are forging collaborations with biopharmaceutical companies to co-develop companion diagnostics, while diagnostics specialists are integrating digital health platforms to streamline data management and remote monitoring.

In the instrument segment, vendors are focusing on modular designs that accommodate both routine immunoassays and high-resolution mass spectrometry on a unified platform. Reagent manufacturers are prioritizing assay miniaturization and reagent stability to support at-home testing and decentralized laboratory models. Meanwhile, informatics providers are enhancing interoperability, embedding artificial intelligence algorithms for result interpretation, and enabling real-time connectivity across multi-site networks.

Emerging players are capitalizing on niche opportunities by developing sensor-based handheld devices and disposable immunoassay cards tailored for field use. Consolidation activities remain prevalent, as companies seek to expand their geographic footprints and accelerate time to market for innovative assays. This dynamic competitive choreography ensures that strategic investments in R&D, partnerships, and platform extensions will continue to delineate market leadership.

Delivering Actionable Recommendations for Industry Leaders Focused on Technology Integration, Strategic Partnerships, and Emerging Market Expansion in Endocrine Diagnostics

Industry leaders should accelerate integration of next-generation technologies by adopting flexible platforms capable of simultaneous immunoassay and mass spectrometry analyses. Such convergence will streamline workflows and lower total cost of ownership. Concurrently, forging strategic partnerships with contract manufacturers and regional distributors can mitigate supply chain vulnerabilities and support rapid market entry in high-growth territories.

Investing in advanced informatics and artificial intelligence capabilities will enhance diagnostic accuracy and speed decision-making. By deploying cloud-based analytics, organizations can enable remote monitoring, predictive maintenance, and performance benchmarking across multi-site operations. Expanding footprint in emerging markets through localized manufacturing partnerships and regulatory collaborations can unlock new revenue streams and bolster global resilience.

Finally, embracing patient-centric service models, such as direct-to-consumer testing and telehealth integration, will differentiate service offerings and foster deeper engagement. By aligning product roadmaps with evolving reimbursement guidelines and payer expectations, companies can ensure sustained market access and drive long-term adoption across diverse healthcare settings.

Detailing the Comprehensive Research Methodology Employing Primary Interviews, Secondary Analysis, and Data Triangulation to Ensure Rigorous Market Insights

This analysis draws upon a rigorous, mixed-methods research design to ensure comprehensive coverage and analytical precision. Primary insights were gathered through structured interviews with C-suite executives, clinical laboratory directors, key opinion leaders, and procurement specialists. These conversations illuminated current operational challenges, unmet needs, and strategic priorities across the value chain.

Secondary data was meticulously compiled from peer-reviewed journals, regulatory agency publications, patent databases, company annual reports, and trade documentation. Each data point underwent triangulation to validate accuracy and minimize bias. Quantitative information was cross-referenced with historical performance indicators and industry benchmarks, while qualitative findings were synthesized through thematic analysis to identify emergent patterns.

A multi-stage validation process, including peer review by domain experts and technical stakeholders, further enhanced the reliability of the conclusions. Through these integrated research methodologies, the report delivers actionable intelligence that is grounded in empirical evidence and reflective of real-world market dynamics.

Concluding Perspectives Emphasizing Strategic Imperatives, Future Outlook, and Integrative Innovations that Will Guide the Evolution of Endocrine Testing Worldwide

The endocrine testing market stands at an inflection point, where rapid technological advancements, shifting regulatory regimes, and evolving patient expectations converge to redefine diagnostic paradigms. Segmentation analysis underscores the diverse needs of clinical laboratories, research entities, and point-of-care providers, while regional insights highlight the importance of adaptive market entry strategies.

Competitive profiling reveals that success will hinge on the ability to integrate multidisciplinary capabilities-from assay innovation and digital health integration to strategic supply chain partnerships. Actionable recommendations emphasize the need for flexible platforms, robust informatics, and targeted expansion into underserved regions.

As industry stakeholders navigate these complexities, sustained collaboration and a relentless focus on quality, compliance, and patient outcomes will dictate long-term resilience. By leveraging the insights contained herein, decision makers can chart a clear path forward, positioning their organizations to capitalize on the next wave of innovation in endocrine diagnostics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Increased awareness of the importance of early detection of endocrine disorders
  • 5.2. Growing adoption of point-of-care testing devices
  • 5.3. Rising demand for personalized medicine approaches driving tailored endocrine therapies
  • 5.4. Integration of artificial intelligence algorithms in endocrine assay interpretation for enhanced diagnostic precision
  • 5.5. Adoption of multiplexed immunoassay platforms for simultaneous screening of multiple hormone biomarkers
  • 5.6. Emergence of home-based endocrine testing kits enabling continuous hormonal monitoring outside clinical settings
  • 5.7. Development of ultra-sensitive mass spectrometry methods for low-abundance hormone quantification in complex matrices
  • 5.8. Expansion of companion diagnostics in oncology revealing endocrine markers predictive of treatment response
  • 5.9. Enhanced regulatory focus on assay standardization and quality control to improve test reliability
  • 5.10. Increasing investment in wearable biosensors for real-time hormonal monitoring and health management

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Endocrine Testing Market, by Type

  • 8.1. Introduction
  • 8.2. Cortisol Test
  • 8.3. Dehydroepiandrosterone Sulfate (DHEAS) Test
  • 8.4. Estradiol (E2) Test
  • 8.5. Human Chorionic Gonadotropin (hCG) Hormone Test
  • 8.6. Insulin Test
  • 8.7. Sex Hormone Tests
  • 8.8. Thyroid Stimulating Hormone (TSH) Test

9. Endocrine Testing Market, by Product Type

  • 9.1. Introduction
  • 9.2. Instruments
    • 9.2.1. Chromatography Systems
    • 9.2.2. Immunoassay Analyzers
    • 9.2.3. Mass Spectrometry Systems
  • 9.3. Reagents & Kits
    • 9.3.1. Calibrators
    • 9.3.2. Control Materials
    • 9.3.3. Diagnostic Kits
  • 9.4. Software And Services
    • 9.4.1. Informatics Solutions
    • 9.4.2. Maintenance Services

10. Endocrine Testing Market, by Sample Type

  • 10.1. Introduction
  • 10.2. Blood
  • 10.3. Saliva
  • 10.4. Urine

11. Endocrine Testing Market, by Technology

  • 11.1. Introduction
  • 11.2. Clinical Chemistry
  • 11.3. Immunoassay
  • 11.4. Monoclonal & Polyclonal Antibody Technologies
  • 11.5. Sensor Technology
  • 11.6. Tandem Mass Spectrometry

12. Endocrine Testing Market, by Disease Type

  • 12.1. Introduction
  • 12.2. Adrenal Disorders
    • 12.2.1. Addison's Disease
    • 12.2.2. Cushing's Syndrome
  • 12.3. Diabetes
  • 12.4. Gonadal Disorders
    • 12.4.1. Hypogonadism
    • 12.4.2. Polycystic Ovary Syndrome
  • 12.5. Thyroid Dysfunction
    • 12.5.1. Hyperthyroidism
    • 12.5.2. Hypothyroidism

13. Endocrine Testing Market, by End User

  • 13.1. Introduction
  • 13.2. Academic Institutions
  • 13.3. Diagnostic Laboratories
  • 13.4. Hospitals & Clinics
  • 13.5. Research Institutes

14. Americas Endocrine Testing Market

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. Argentina

15. Europe, Middle East & Africa Endocrine Testing Market

  • 15.1. Introduction
  • 15.2. United Kingdom
  • 15.3. Germany
  • 15.4. France
  • 15.5. Russia
  • 15.6. Italy
  • 15.7. Spain
  • 15.8. United Arab Emirates
  • 15.9. Saudi Arabia
  • 15.10. South Africa
  • 15.11. Denmark
  • 15.12. Netherlands
  • 15.13. Qatar
  • 15.14. Finland
  • 15.15. Sweden
  • 15.16. Nigeria
  • 15.17. Egypt
  • 15.18. Turkey
  • 15.19. Israel
  • 15.20. Norway
  • 15.21. Poland
  • 15.22. Switzerland

16. Asia-Pacific Endocrine Testing Market

  • 16.1. Introduction
  • 16.2. China
  • 16.3. India
  • 16.4. Japan
  • 16.5. Australia
  • 16.6. South Korea
  • 16.7. Indonesia
  • 16.8. Thailand
  • 16.9. Philippines
  • 16.10. Malaysia
  • 16.11. Singapore
  • 16.12. Vietnam
  • 16.13. Taiwan

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Bio-Rad Laboratories Inc
    • 17.3.2. bioMerieux SA
    • 17.3.3. Abbott Laboratories
    • 17.3.4. ACON Laboratories, Inc.
    • 17.3.5. Agilent Technologies, Inc.
    • 17.3.6. BioCheck Inc.
    • 17.3.7. Biogenix Inc. Pvt. Ltd
    • 17.3.8. Blueprint Genetics Oy
    • 17.3.9. Creative Diagnostics
    • 17.3.10. Danaher Corporation
    • 17.3.11. Diagnostic Automation/Cortez Diagnostics Inc.
    • 17.3.12. DiaSorin S.p.A.
    • 17.3.13. Eagle Biosciences
    • 17.3.14. EKF Diagnostics Holdings Plc
    • 17.3.15. Eurofins Analytical Laboratories Inc.
    • 17.3.16. Getein Biotech, Inc.
    • 17.3.17. Laboratory Corporation of America Holdings
    • 17.3.18. MP Biomedicals, LLC
    • 17.3.19. Ortho-Clinical Diagnostics, Inc.
    • 17.3.20. Quest Diagnostics Incorporated
    • 17.3.21. Randox Laboratories Ltd.
    • 17.3.22. Shenzhen New Industries Biomedical Engineering Co., Ltd.
    • 17.3.23. Siemens Healthcare GmbH
    • 17.3.24. Thermo Fisher Scientific Inc.
    • 17.3.25. Trivitron Healthcare
    • 17.3.26. Eli Science Inc.
    • 17.3.27. F. Hoffmann-La Roche Ltd

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix

LIST OF FIGURES

  • FIGURE 1. ENDOCRINE TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL ENDOCRINE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 20. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. ASIA-PACIFIC ENDOCRINE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. ASIA-PACIFIC ENDOCRINE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. ENDOCRINE TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. ENDOCRINE TESTING MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 27. ENDOCRINE TESTING MARKET: RESEARCHAI
  • FIGURE 28. ENDOCRINE TESTING MARKET: RESEARCHSTATISTICS
  • FIGURE 29. ENDOCRINE TESTING MARKET: RESEARCHCONTACTS
  • FIGURE 30. ENDOCRINE TESTING MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. ENDOCRINE TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ENDOCRINE TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ENDOCRINE TESTING MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY CORTISOL TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY CORTISOL TEST, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY DEHYDROEPIANDROSTERONE SULFATE (DHEAS) TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY DEHYDROEPIANDROSTERONE SULFATE (DHEAS) TEST, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY ESTRADIOL (E2) TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY ESTRADIOL (E2) TEST, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY HUMAN CHORIONIC GONADOTROPIN (HCG) HORMONE TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY HUMAN CHORIONIC GONADOTROPIN (HCG) HORMONE TEST, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY INSULIN TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY INSULIN TEST, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY SEX HORMONE TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY SEX HORMONE TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY THYROID STIMULATING HORMONE (TSH) TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY THYROID STIMULATING HORMONE (TSH) TEST, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY CHROMATOGRAPHY SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY MASS SPECTROMETRY SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY MASS SPECTROMETRY SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY CALIBRATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY CALIBRATORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY CONTROL MATERIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY CONTROL MATERIALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY DIAGNOSTIC KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY DIAGNOSTIC KITS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY INFORMATICS SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY INFORMATICS SOLUTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY MAINTENANCE SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY MAINTENANCE SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY BLOOD, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY SALIVA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY URINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY MONOCLONAL & POLYCLONAL ANTIBODY TECHNOLOGIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY MONOCLONAL & POLYCLONAL ANTIBODY TECHNOLOGIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY SENSOR TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY SENSOR TECHNOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY TANDEM MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY TANDEM MASS SPECTROMETRY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY ADDISON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY ADDISON'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY CUSHING'S SYNDROME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY CUSHING'S SYNDROME, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY DIABETES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY DIABETES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY HYPOGONADISM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY HYPOGONADISM, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY POLYCYSTIC OVARY SYNDROME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY POLYCYSTIC OVARY SYNDROME, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY HYPERTHYROIDISM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY HYPERTHYROIDISM, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY HYPOTHYROIDISM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY HYPOTHYROIDISM, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ENDOCRINE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 115. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 117. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 119. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 121. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2025-2030 (USD MILLION)
  • TABLE 123. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 125. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 127. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 129. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 131. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 133. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2025-2030 (USD MILLION)
  • TABLE 135. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 137. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS ENDOCRINE TESTING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 139. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 141. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 143. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 144. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 145. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 146. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 147. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2024 (USD MILLION)
  • TABLE 148. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2025-2030 (USD MILLION)
  • TABLE 149. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 151. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 152. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 153. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 155. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 156. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 157. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 158. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 159. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2018-2024 (USD MILLION)
  • TABLE 160. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2025-2030 (USD MILLION)
  • TABLE 161. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 163. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 164. UNITED STATES ENDOCRINE TESTING MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 165. CANADA ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. CANADA ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 167. CANADA ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. CANADA ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 169. CANADA ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 170. CANADA ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 171. CANADA ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 172. CANADA ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 173. CANADA ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2024 (USD MILLION)
  • TABLE 174. CANADA ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2025-2030 (USD MILLION)
  • TABLE 175. CANADA ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. CANADA ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 177. CANADA ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 178. CANADA ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 179. CANADA ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. CANADA ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 181. CANADA ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 182. CANADA ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 183. CANADA ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 184. CANADA ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 185. CANADA ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2018-2024 (USD MILLION)
  • TABLE 186. CANADA ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2025-2030 (USD MILLION)
  • TABLE 187. CANADA ENDOCRINE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. CANADA ENDOCRINE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 189. MEXICO ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. MEXICO ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 191. MEXICO ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. MEXICO ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 193. MEXICO ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 194. MEXICO ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 195. MEXICO ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 196. MEXICO ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 197. MEXICO ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2024 (USD MILLION)
  • TABLE 198. MEXICO ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2025-2030 (USD MILLION)
  • TABLE 199. MEXICO ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. MEXICO ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 201. MEXICO ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 202. MEXICO ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 203. MEXICO ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. MEXICO ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 205. MEXICO ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 206. MEXICO ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 207. MEXICO ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 208. MEXICO ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 209. MEXICO ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2018-2024 (USD MILLION)
  • TABLE 210. MEXICO ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2025-2030 (USD MILLION)
  • TABLE 211. MEXICO ENDOCRINE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. MEXICO ENDOCRINE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 213. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 215. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 217. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 218. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 219. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 220. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 221. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2024 (USD MILLION)
  • TABLE 222. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2025-2030 (USD MILLION)
  • TABLE 223. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 225. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 226. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 227. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 229. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 230. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 231. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 232. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 233. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2018-2024 (USD MILLION)
  • TABLE 234. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2025-2030 (USD MILLION)
  • TABLE 235. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. BRAZIL ENDOCRINE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 237. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 239. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 241. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 242. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 243. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 244. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 245. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2024 (USD MILLION)
  • TABLE 246. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2025-2030 (USD MILLION)
  • TABLE 247. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 249. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 250. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 251. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 253. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 254. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 255. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 256. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 257. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2018-2024 (USD MILLION)
  • TABLE 258. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2025-2030 (USD MILLION)
  • TABLE 259. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. ARGENTINA ENDOCRINE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2025-2030 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2025-2030 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA ENDOCRINE TESTING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 287. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 289. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 291. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 292. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 293. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 295. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2024 (USD MILLION)
  • TABLE 296. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2025-2030 (USD MILLION)
  • TABLE 297. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 299. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 300. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 301. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 303. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 304. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 305. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 306. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 307. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2018-2024 (USD MILLION)
  • TABLE 308. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2025-2030 (USD MILLION)
  • TABLE 309. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 310. UNITED KINGDOM ENDOCRINE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 311. GERMANY ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. GERMANY ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 313. GERMANY ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. GERMANY ENDOCRINE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 315. GERMANY ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 316. GERMANY ENDOCRINE TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 317. GERMANY ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 318. GERMANY ENDOCRINE TESTING MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 319. GERMANY ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2024 (USD MILLION)
  • TABLE 320. GERMANY ENDOCRINE TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, 2025-2030 (USD MILLION)
  • TABLE 321. GERMANY ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. GERMANY ENDOCRINE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 323. GERMANY ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 324. GERMANY ENDOCRINE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 325. GERMANY ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 326. GERMANY ENDOCRINE TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 327. GERMANY ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 328. GERMANY ENDOCRINE TESTING MARKET SIZE, BY ADRENAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 329. GERMANY ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 330. GERMANY ENDOCRINE TESTING MARKET SIZE, BY GONADAL DISORDERS, 2025-2030 (USD MILLION)
  • TABLE 331. GERMANY ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2018-2024 (USD MILLION)
  • TABLE 332. GERMANY ENDOCRINE TESTING MARKET SIZE, BY THYROID DYSFUNCTION, 2025-2030 (USD MILLION)
  • TABLE 333. GERMANY ENDOCRINE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 334. GERMANY ENDOCRINE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 335. FRANCE ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. FRANCE ENDOCRINE TESTING MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)

TA